Synonyms: CKD-314 | CKD314 | FUT-175 | Nafabelltan®
nafamostat is an approved drug (Japan only)
Compound class:
Synthetic organic
Comment: Nafamostat is a guanidinobenzoate-containing inhibitor, with activity against a range of serine proteases. Some data is attached to nafamostat mesylate (PubChem CID 5311180).
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Chen X, Numata T, Li M, Mori Y, Orser BA, Jackson MF, Xiong ZG, MacDonald JF. (2010)
The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations. Mol Brain, 3: 38. [PMID:21122141] |
2. Hays SJ, Caprathe BW, Gilmore JL, Amin N, Emmerling MR, Michael W, Nadimpalli R, Nath R, Raser KJ, Stafford D et al.. (1998)
2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease. J Med Chem, 41 (7): 1060-7. [PMID:9544206] |
3. Hoffmann M, Schroeder S, Kleine-Weber H, Müller MA, Drosten C, Pöhlmann S. (2020)
Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19. Antimicrob Agents Chemother, 64 (6). DOI: 10.1128/AAC.00754-20 [PMID:32312781] |
4. Mori S, Itoh Y, Shinohata R, Sendo T, Oishi R, Nishibori M. (2003)
Nafamostat mesilate is an extremely potent inhibitor of human tryptase. J Pharmacol Sci, 92 (4): 420-3. [PMID:12939527] |
5. The University of Tokyo Hospital.
Therapy with Favipiravir and Nafamostat in Patients with COVID-19. Accessed on 18/05/2020. Modified on 18/05/2020. The University of Tokyo Hospital/articles, https://www.u-tokyo.ac.jp/focus/en/articles/z0103_00019.html |
6. Ugawa S, Ishida Y, Ueda T, Inoue K, Nagao M, Shimada S. (2007)
Nafamostat mesilate reversibly blocks acid-sensing ion channel currents. Biochem Biophys Res Commun, 363 (1): 203-8. [PMID:17826743] |
7. Yamamoto M, Matsuyama S, Li X, Takeda M, Kawaguchi Y, Inoue JI, Matsuda Z. (2016)
Identification of Nafamostat as a Potent Inhibitor of Middle East Respiratory Syndrome Coronavirus S Protein-Mediated Membrane Fusion Using the Split-Protein-Based Cell-Cell Fusion Assay. Antimicrob Agents Chemother, 60 (11): 6532-6539. [PMID:27550352] |